Related Experiment Video
Updated: Apr 18, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.6K
New Thrombotic Events in Ischemic Stroke Patients with Elevated Factor VIII
Brittany M Gouse1, Amelia K Boehme2, Dominique J Monlezun1
1Stroke Program, Department of Neurology, Tulane University School of Medicine, 1440 Canal Street, TB-52, Suite 1000, New Orleans, LA 70112-2715, USA.
Thrombosis
|January 13, 2015
Summary
Elevated Factor VIII (FVIII) levels in acute ischemic stroke (AIS) patients correlate with a higher risk of recurrent thrombotic events (RTEs) during hospitalization. This finding suggests FVIII may be a biomarker for stroke recurrence and associated complications.
Area of Science:
- Neurology
- Hematology
- Thrombosis Research
Background:
- Elevated Factor VIII (FVIII) levels are linked to arterial and venous thrombosis.
- High FVIII is common in acute ischemic stroke (AIS), but its role in recurrent events is unclear.
Purpose of the Study:
- To investigate if elevated FVIII increases the risk of recurrent thrombotic events (RTEs) after AIS.
- To assess the association between FVIII levels and in-hospital RTEs in AIS patients.
Main Methods:
- Retrospective analysis of 298 consecutive AIS patients with measured FVIII levels.
- Comparison of baseline characteristics and RTE occurrence between patients with and without elevated FVIII.
Main Results:
- 68.1% of AIS patients had elevated FVIII levels.
- Patients with elevated FVIII showed significantly higher rates of in-hospital RTEs (18.7% vs. 8.4%, P=0.0218).
- Elevated FVIII remained associated with RTEs after adjusting for stroke severity and etiology (OR 1.01, P=0.0013).
Conclusions:
- Elevated FVIII is significantly associated with a higher frequency of in-hospital RTEs in AIS patients.
- In-hospital RTEs in this cohort were linked to increased major disability.
- Further research is warranted to explore FVIII as a potential biomarker for predicting RTEs post-AIS.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
475
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
475
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.9K
01:30Venous Thrombosis I: Introduction
762
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
762
01:24Disorders of Hemostasis
2.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
16.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
16.2K